TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05091528

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“Sponsor decision based on strategic re-alignment”

The sponsor’s own words in the registry.

Life of this trial

202120222023Registered2021-10-12Started2022-02-08Stopped2022-07-07Results posted2022-08-18

Vital statistics

Status
Terminated
Phase
Phase 1, Phase 2
Sponsor
Silverback Therapeutics
Sponsor type
Industry
Conditions
HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Colorectal Cancer; HER2-expressing Non-small Cell Lung Cancer
Interventions
SBT6050; trastuzumab deruxtecan; tucatinib; trastuzumab; capecitabine; trastuzumab deruxtecan
Participants
2
Sites
1
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.